0.89
+0.0258(+3.00%)
Currency In USD
| Previous Close | 0.86 |
| Open | 0.85 |
| Day High | 0.89 |
| Day Low | 0.85 |
| 52-Week High | 1.19 |
| 52-Week Low | 0.54 |
| Volume | 35,093 |
| Average Volume | 461,548 |
| Market Cap | 10.32M |
| PE | -0.59 |
| EPS | -1.5 |
| Moving Average 50 Days | 0.82 |
| Moving Average 200 Days | 0.84 |
| Change | 0.03 |
If you invested $1000 in Biofrontera Inc. (BFRI) since IPO date, it would be worth $10.04 as of February 21, 2026 at a share price of $0.886. Whereas If you bought $1000 worth of Biofrontera Inc. (BFRI) shares 3 years ago, it would be worth $55.08 as of February 21, 2026 at a share price of $0.886.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities
GlobeNewswire Inc.
Feb 17, 2026 2:15 PM GMT
Phase 1 maximal-use pharmacokinetics (PK) study completed in support of planned U.S. label expansionData to complement previously announced positive Phase 3 efficacy results on extremities, neck and trunkSupplemental NDA submission for extremities, n
Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma
GlobeNewswire Inc.
Feb 11, 2026 2:15 PM GMT
Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026If approved, Ameluz® would be the first and only PDT photosensitizer indicated for the treatment of superficial Basal Cell Carcinoma (sBCC) in the USBCC is the most c
Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint
GlobeNewswire Inc.
Feb 09, 2026 2:15 PM GMT
Study findings met its primary endpoint and showed highly statistically significant superiority for Ameluz® vs. vehicle gel (p<0.0003)Actinic keratosis (AK) is the most common skin condition diagnosed by US dermatologists1If left untreated, AK may pr